Beyond the genome--SMi Conference 27-28 January 2003, London, UK.
Over a decade of astonishing developments, genomics and proteomics have promised a fundamentally new approach to drug discovery. Although there has been an undeniable increase in the range of potential targets available, this has not led to an increased output of the drug discovery pipeline into the clinic. With tighter markets and increasing competition, the major pharmaceutical companies are under intense pressure to achieve rapid, concrete delivery of those early promises, but there remain acute problems in the genes-to-drugs pipeline. This meeting showcased a range of novel approaches from proteomics and bioinformatics to address these problems. A common theme in the range of proteomics offerings was the prioritization of potential novel targets on the basis of their accessibility to drugs and their functional link to disease phenotypes. Informatics and in silico offerings also concentrated on fast, accurate, drug-focused workflows built on large integrative databases and novel data-mined algorithms.
Swinton
Jonathan
J
Preoteom Ltda. Babraham Hall, Babraham Cambridge, UK. jswinton@proteom.com
Sheridan
Joe M
JM
Henning
Stefan W
SW
D000818:Animals; D016678:Genome; D023281:Genomics / Q000379:methods* / Q000639:trends; D006801:Humans; D040901:Proteomics / Q000379:methods / Q000639:trends; D013678:Technology, Pharmaceutical / Q000379:methods* / Q000639:trends